Solid Biosciences (SLDB) Current Assets (2017 - 2026)

Solid Biosciences has disclosed Current Assets across 10 years of filings, most recently posting $396.8 million for Q1 2026.

• Current Assets for Q1 2026 came in at $396.8 million, up 26.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $396.8 million (up 26.6% YoY), and the FY2025 annual result was $205.5 million, up 30.61% from the prior year.
• Current Assets came in at $396.8 million for Q1 2026 at Solid Biosciences, up from $205.5 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $396.8 million in Q1 2026 to a low of $129.7 million in Q4 2023.
• The 5-year median for Current Assets is $197.6 million (2024), against an average of $209.4 million.
• Across the five-year window, Current Assets sank 40.93% in 2023 and surged 46.32% in 2025, its largest moves.
• Solid Biosciences' Current Assets stood at $219.6 million in 2022, then tumbled by 40.93% to $129.7 million in 2023, then advanced by 21.25% to $157.3 million in 2024, then jumped by 30.61% to $205.5 million in 2025, then jumped by 93.13% to $396.8 million in 2026.
• The last three Current Assets figures came in at $396.8 million (Q1 2026), $205.5 million (Q4 2025), and $244.9 million (Q3 2025), per Business Quant data.